I have a very jaded view of the public markets.  Traditional business media imo doesn't start beating the dinner bell until a stock has already made huge gains in my view.  

Like most here I can see RVX attaining a valuation in excess of Beacon's $8.55 12 month target...much higher.  I don't think tada's high end estimate of $100+ is outside the realm of possibility.  

I don't have an extensive network of people that I know in the media, but I do know some.....and I'm starting to share.  I would love to hear something like this reported during the business news....who knows, maybe it'll happen.

Calgary based Biotech Resverlogix (Rez-Vuhr-Lodge-Icks) started trading last week at $1.53 and closed at $2.20 on Friday for a gain of 67 cents or 44%.  The company announced approval of an $87 million (Canadian funds) investment by leading Chinese Pharmaceutical company Shenzhen Hepalink, the world's leading producer of Herparin Sodium, a blood thinner.  Analyst David Kideckel of Beacon Securities recently published a report referring to Resverlogix as one of Canada's most undervalued and impressive Biotechnology companies, he rated the stock a buy with a 12 month price target of $8.55.  The company currently has a drug, Apabetalone (Ah-Pah-Bet-Alone) in a Phase III clinical trial for the treatment of Cardio Vascular Disease....